(Reuters) -The U.S. Centers for Disease Control and Prevention’s revamped vaccine advisory panel on Wednesday postponed its vote on the use of respiratory syncytial virus therapies to Thursday.
The panel, which has convened for a closely watched two-day meeting, was discussing the use of AstraZeneca and Sanofi’s Beyfortus and Merck’s Enflonsia.
(Reporting by Christy Santhosh and Bhanvi Satija in Bengaluru; Editing by Maju Samuel)
Comments